Skip to application
All calculators and tools

Preparation. Administration. Evidence.

IV Dilution &
Medication Reference

Search 255 medications, read preserved historical references, and inspect separately reviewed preparation statements. Full monograph updates remain pending.

Version 6.4Release date 2026-11-04For healthcare professionals
Back to resultsA-Z list

Medication reference

Adakveo (crizanlizumab-tmca)

Monograph awaiting updateThis monograph will be updated in the future.

Jump to a section
Search DailyMed products (opens in a new tab)

Historical source. Current clinical review is incomplete. This monograph will be updated in the future.

ADAKVEO® (crizanlizumab-tmca) (opens in a new tab)Original source URL: https://globalrph.com/dilution/adakveo-crizanlizumab-tmca/ | Retrieved 2026-11-04

Source dates, location and integrity

This historical article is separate from the reviewed claim cards. Product formulations and source dates may differ.

Original source URL
https://globalrph.com/dilution/adakveo-crizanlizumab-tmca/ (opens in a new tab)
Source date
Not established in the retrieved source
Retrieved
2026-11-04T19:45:17.461555+00:00
Source location
div.post-content
Packaged content SHA-256
94aeba9efef38082d1fe1469894f19974205a821252f3b3c65179c689db31b77
Original response SHA-256
8bf0df46464b98bfada4e7a0a9f528121f67c1c9285a72d2e67537f9bad2eff8
Source body SHA-256
c8db73411e44e6c9d4e7a3f44e99173fc18f3ca5dd8f8fc10ad25e6713ed736e

ADAKVEO® (crizanlizumab-tmca)

PRESCRIBING HIGHLIGHTS: Please see package insert for additional information and possible updates to ensure safe and effective use of this medication. The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. Please read the disclaimer carefully BEFORE accessing or using this site. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.

Drug UPDATES: [Drug information (pdf)]
PACKAGE INSERT -Dosing: Click (+) next to Dosage and Administration section (drug info link)

Usual Diluents Return to article top

NS, D5W

Standard Dilutions [Amt of drug] [Infusion vol] [Infusion rate] Return to article top

[5 mg/kg ] [100 ml (total volume)] [30 minutes]

Volume (mL) Adakveo=
[patient's body weight (kg) x 5 mg/kg]
-------------------------------------------
10 (Solution is 10 mg/mL)

Remove a volume of 0.9% Sodium Chloride Injection or 5% Dextrose Injection from the infusion bag/container that is equal to the required volume of ADAKVEO solution.

Must use a 0.2 micron inline filter.

2.1 Recommended Dosage

Administer ADAKVEO 5 mg/kg by intravenous infusion over a period of 30 minutes at Week 0, Week 2, and every 4 weeks thereafter.

If a dose is missed, administer ADAKVEO as soon as possible.

If ADAKVEO is administered within 2 weeks after the missed dose, continue dosing according to the patient's original schedule.

If ADAKVEO is administered more than 2 weeks after the missed dose, continue dosing every 4 weeks thereafter.

ADAKVEO may be given with or without hydroxyurea.

2.2 Preparation and Administration

ADAKVEO should be prepared and administered by a healthcare professional.

Preparation

  • Use aseptic technique to prepare the solution for infusion.
  • Calculate the dose (mg) and the total volume (mL) of ADAKVEO solution required, and the number of ADAKVEO vials needed based on the patient's actual body weight.
    • Prepare 5 mg of ADAKVEO per kg of actual body weight.
  • Calculate the volume of ADAKVEO to be used according to the following equation:

    Volume (mL)= [patient's body weight (kg) x 5 mg/kg] / 10

Dilution

Dilute ADAKVEO in 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP to a total volume of 100 mL for intravenous infusion as follows:

  1. Obtain the number of vials required. One vial is needed for every 10 mL of ADAKVEO.
  2. Bring vials to room temperature for a maximum of 4 hours prior to the start of preparation (piercing the first vial).
  3. Visually inspect the vials.
    • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
    • ADAKVEO is clear to opalescent, colorless or may have a slightly brownish-yellow tint.
    • Do not use if particles are present in the solution.
  4. Obtain a 100 mL 0.9% Sodium Chloride Injection or 5% Dextrose Injection infusion bag/container.
    • Infusion bags/containers must be made of either polyvinyl chloride (PVC), polyethylene (PE), or polypropylene (PP).
  5. Remove a volume of 0.9% Sodium Chloride Injection or 5% Dextrose Injection from the infusion bag/container that is equal to the required volume of ADAKVEO solution.
  6. Withdraw the necessary amount of ADAKVEO solution and dilute by adding to the infusion bag/container containing 0.9% Sodium Chloride Injection or 5% Dextrose Injection.
    • The volume of ADAKVEO added to the infusion bag/container should not exceed 96 mL.
  7. Gently invert the infusion bag to mix the diluted solution. DO NOT SHAKE.
  8. Single-dose vials. Discard unused portion.

Storage Conditions of the Diluted Solution

Administer ADAKVEO diluted solution as soon as possible. If not administered immediately, store the prepared solution either:

  • At room temperature up to 25°C (77°F) for no more than 4.5 hours from the start of the preparation (piercing the first vial) to the completion of infusion.
  • Under refrigeration at 2°C to 8°C (36°F to 46°F) for no more than 24 hours, from the start of the time of the preparation (piercing the first vial) to the completion of infusion. This includes the storage of the diluted solution and the time to warm up to room temperature. Protect the diluted solution from light during storage under refrigeration.

Administration

  • Administer ADAKVEO diluted solution by intravenous infusion over a period of 30 minutes through an intravenous line, which must contain a sterile, nonpyrogenic 0.2 micron inline filter.
  • No incompatibilities have been observed between ADAKVEO and infusion sets composed of PVC, polyethylene (PE-lined PVC), polyurethane (PU), and in-line filter membranes composed of polyethersulfone (PES, neutral and positively charged), positively charged polyamide (PA), and polysulphone (PSU).
  • Do not mix or coadminister with other drugs through the same intravenous line.
  • After administration of ADAKVEO, flush the line with at least 25 mL of 0.9% Sodium Chloride or 5% Dextrose Injection.
  • Dispose of any unused product or waste material in accordance with local requirements.

Description:
Crizanlizumab-tmca is a P-selectin blocker humanized IgG2 kappa monoclonal antibody that binds to P-selectin. Crizanlizumab-tmca is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. It is composed of 2 heavy chains, each containing 448 amino acids, and 2 light chains each containing 218 amino acids, with a theoretical molecular weight of approximately 146 kDa.

ADAKVEO (crizanlizumab-tmca) injection is supplied as a sterile, preservative-free, clear to opalescent, colorless to slightly brownish-yellow solution for dilution and subsequent administration by intravenous infusion. Each 10 mL vial contains 100 mg crizanlizumab-tmca, citric acid (5.4 mg), polysorbate 80 (2 mg), sodium citrate (50.5 mg), sucrose (753.3 mg) and water for injection with a pH of 6.

CLINICAL PHARMACOLOGY: Return to article top

Mechanism of Action:

Crizanlizumab-tmca is a humanized IgG2 kappa monoclonal antibody that binds to P-selectin and blocks interactions with its ligands, including P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab-tmca can also dissociate preformed P-selectin/PSGL-1 complex.

Binding P-selectin on the surface of the activated endothelium and platelets blocks interactions between endothelial cells, platelets, red blood cells, and leukocytes.

INDICATIONS AND USAGE Return to article top

INDICATIONS AND USAGE:
ADAKVEO® is indicated to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease.

CONTRAINDICATIONS Return to article top

Contraindications:

None.

WARNINGS AND PRECAUTIONS:
5.1 Infusion-Related Reactions
In the SUSTAIN clinical trial, infusion-related reactions (defined as occurring during/within 24 hours of infusion) were observed in 2 (3%) patients treated with ADAKVEO 5 mg/kg [see Adverse Reactions (6.1)].

In the postmarketing setting, cases of infusion-related reactions, including severe pain events, have been reported, which required hospitalizations. The majority of these infusion-related reactions occurred during the first and second infusions. The management of pain events has included acetaminophen, NSAIDs, opioids, antihistamines, intravenous fluids, and/or oxygen therapy. Some patients have also experienced subsequent complications, such as acute chest syndrome and fat embolism, particularly those treated with steroids.

Monitor for and advise patients of signs and symptoms of infusion-related reactions, which may include pain in various locations, headache, fever, chills, nausea, vomiting, diarrhea, fatigue, dizziness, pruritus, urticaria, sweating, and shortness of breath or wheezing.

Discontinue ADAKVEO infusion for severe infusion-related reactions and institute appropriate medical care [see Dosage and Administration (2.3)].

For management recommendations of a mild or moderate infusion-related reaction [see Dosage and Administration (2.3)].

Exercise caution with corticosteroids in patients with sickle cell disease unless clinically indicated (e.g., treatment of anaphylaxis).

5.2 Laboratory Test Interference
Interference with automated platelet counts (platelet clumping) has been observed following administration of ADAKVEO, in particular, when blood samples were collected in tubes containing ethylenediaminetetraacetic acid (EDTA). Mitigation strategies are recommendeD.

ADVERSE REACTIONS Return to article top

ADVERSE REACTIONS:

Most common adverse reactions (incidence > 10%) are nausea, arthralgia, back pain, abdominal pain, and pyrexia.

See PACKAGE INSERT for PATIENT COUNSELING INFORMATION and Medication Guide. Drug information (pdf)

DOSAGE AND ADMINISTRATION Return to article top

DOSAGE AND ADMINISTRATION:
2.1 Recommended Dosage

Administer ADAKVEO 5 mg/kg by intravenous infusion over a period of 30 minutes at Week 0, Week 2, and every 4 weeks thereafter.

If a dose is missed, administer ADAKVEO as soon as possible.

If ADAKVEO is administered within 2 weeks after the missed dose, continue dosing according to the patient's original schedule.

If ADAKVEO is administered more than 2 weeks after the missed dose, continue dosing every 4 weeks thereafter.

ADAKVEO may be given with or without hydroxyurea.

2.2 Preparation and Administration

ADAKVEO should be prepared and administered by a healthcare professional.

Preparation

  • Use aseptic technique to prepare the solution for infusion.
  • Calculate the dose (mg) and the total volume (mL) of ADAKVEO solution required, and the number of ADAKVEO vials needed based on the patient's actual body weight.
    • Prepare 5 mg of ADAKVEO per kg of actual body weight.
  • Calculate the volume of ADAKVEO to be used according to the following equation:

    Volume (mL)= [patient's body weight (kg) x 5 mg/kg] / 10

Dilution

Dilute ADAKVEO in 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP to a total volume of 100 mL for intravenous infusion as follows:

  1. Obtain the number of vials required. One vial is needed for every 10 mL of ADAKVEO.
  2. Bring vials to room temperature for a maximum of 4 hours prior to the start of preparation (piercing the first vial).
  3. Visually inspect the vials.
    • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
    • ADAKVEO is clear to opalescent, colorless or may have a slightly brownish-yellow tint.
    • Do not use if particles are present in the solution.
  4. Obtain a 100 mL 0.9% Sodium Chloride Injection or 5% Dextrose Injection infusion bag/container.
    • Infusion bags/containers must be made of either polyvinyl chloride (PVC), polyethylene (PE), or polypropylene (PP).
  5. Remove a volume of 0.9% Sodium Chloride Injection or 5% Dextrose Injection from the infusion bag/container that is equal to the required volume of ADAKVEO solution.
  6. Withdraw the necessary amount of ADAKVEO solution and dilute by adding to the infusion bag/container containing 0.9% Sodium Chloride Injection or 5% Dextrose Injection.
    • The volume of ADAKVEO added to the infusion bag/container should not exceed 96 mL.
  7. Gently invert the infusion bag to mix the diluted solution. DO NOT SHAKE.
  8. Single-dose vials. Discard unused portion.

Storage Conditions of the Diluted Solution

Administer ADAKVEO diluted solution as soon as possible. If not administered immediately, store the prepared solution either:

  • At room temperature up to 25°C (77°F) for no more than 4.5 hours from the start of the preparation (piercing the first vial) to the completion of infusion.
  • Under refrigeration at 2°C to 8°C (36°F to 46°F) for no more than 24 hours, from the start of the time of the preparation (piercing the first vial) to the completion of infusion. This includes the storage of the diluted solution and the time to warm up to room temperature. Protect the diluted solution from light during storage under refrigeration.

Administration

  • Administer ADAKVEO diluted solution by intravenous infusion over a period of 30 minutes through an intravenous line, which must contain a sterile, nonpyrogenic 0.2 micron inline filter.
  • No incompatibilities have been observed between ADAKVEO and infusion sets composed of PVC, polyethylene (PE-lined PVC), polyurethane (PU), and in-line filter membranes composed of polyethersulfone (PES, neutral and positively charged), positively charged polyamide (PA), and polysulphone (PSU).
  • Do not mix or coadminister with other drugs through the same intravenous line.
  • After administration of ADAKVEO, flush the line with at least 25 mL of 0.9% Sodium Chloride or 5% Dextrose Injection.
  • Dispose of any unused product or waste material in accordance with local requirements.
2.3 Management of Infusion-Related Reactions

No dose reductions are recommended. Management for infusion-related reactions for ADAKVEO is described in Table 1.

Table 1. Recommended Management for Infusion-Related Reactions
Severity of Adverse Reaction Recommendation
Mild to moderate infusion-related reactions
  • Temporarily interrupt the infusion or slow the rate of infusion
  • Initiate symptomatic treatmenta (e.g., acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, antihistamines, intravenous fluids, and/or oxygen therapy)
  • For subsequent infusions, consider premedication and/or reduce the infusion rate
Severe infusion-related reactions
  • Discontinue infusion
  • Institute appropriate medical carea
  • Consider permanent discontinuation of ADAKVEO

aExercise caution with the use of corticosteroids in patients with sickle cell disease unless clinically indicated (e.g., treatment of anaphylaxis).

DOSAGE FORMS AND STRENGTHS:
Injection: 100 mg/10 mL (10 mg/mL) as a clear to opalescent, colorless to slightly brownish-yellow solution in a single-dose vial.

Storage and Stability Return to article top


How Supplied

ADAKVEO (crizanlizumab-tmca) injection is a sterile, clear to opalescent, colorless to slightly brownish-yellow solution for intravenous infusion supplied as:

Carton containing one 100 mg/10 mL (10 mg/mL) single-dose vial NDC 0078-0883-61

The single-dose vial has a rubber stopper and an aluminum cap with a plastic flip-off disk. Each 10 mL vial is made of Type 1 glass.

Storage and Handling

Store and transport refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light.
Do not shake. Do not freeze.

Open this historical article on its own

Product identifiers and clinical review status

This monograph will be updated in the future. Historical material is available where present in the original sources; full current exact-product and claim-level review remains pending.

Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.

What remains to be completed
  • Retrievable exact-product SPL XML with version, revision, retrieval date and reproducible hash
  • Clinically reviewed, individually identified statements with two exact source mappings
  • Exact formulation, strength, container, manufacturer/labeler, application and NDC reconciliation
  • Renal-function methods and dialysis/CRRT modality review where applicable
  • Mechanism provenance, clinical source disagreements and full medication-specific safety reconciliation

Supplemental historical fields

Restored-data provenance and review notes

Source release: 2026-08-31. Current clinical review is incomplete. Original uses of current, verified, or normalized describe the historical source. They do not inherit the status of separately reviewed statements. Product formulations and source dates can differ.

Current review annotations for historical renal, dialysis, mechanism, and product fieldsSeparate renal reference: Open Renal Dosing Master (opens in a new tab)
Renal
Status
not_locally_normalized
Original classification
current_label_review_required
Entries
    General note
    Preserve the source-specific renal-function basis. An indexed CrCl table is not interchangeable with unindexed CrCl or eGFR. Generic advice to check a method does not identify the equation for a dose row.
    Dialysis
    Status
    no_local_structured_regimen
    Entries
      General note
      Named modality alone does not establish applicability. CRRT subtype, effluent rate, residual renal function, timing and interruptions require review. Historical absence is not evidence that no guidance exists.
      Mechanisms
      • Source kind
        first_look
        Local pointer
        /mechanism
        Original level
        drug_specific
        Provenance classification
        historical_drug_specific_uncorroborated
        Label derived verified
        false
        Independently corroborated
        false
        Exact label section
        Not recorded
        Original source note
        Not recorded
        Review status
        historical_unverified
        Note
        Drug-specific wording in the old file is not proof of independent corroboration or an exact label locator. Consult separately published current mechanism claims where present.
      Future update
      Status
      pending_review
      Message
      This monograph will be updated in the future as current exact-product and claim-level review is completed.
      Source unavailable
      false
      Reason
      The historical content is restored; comprehensive contemporary verification remains incomplete.
      Historical first look: uses, mechanism, dosing context, and administration

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      adakveo-crizanlizumab-tmca
      Source IDH51-C846A25DE9F6BD4874808DBA
      Generic name
      Adakveo (crizanlizumab-tmca)
      Source IDH51-FFF10DCFD5F0DC588EF00371
      Class
      Biologics and immunotherapy
      Source IDH51-EB39EAD7C3C90D8C06E513C7
      Subclass
      Legacy GlobalRPh directory entry
      Source IDH51-93015B6517D78CD3D4807F79
      Primary uses
      1. The current labeled immune, hematologic, neurologic, metabolic, or inflammatory indication for this targeted biologic.
        Source IDH51-E1CD5393E5BD7299C9D9CC17
      Mechanism
      Binds P-selectin and reduces adhesion among activated endothelium, platelets, leukocytes, and sickled erythrocytes.
      Source IDH51-9A810FCE155B8E94855B7F1F
      Mechanism level
      drug_specific
      Source IDH51-C15D95DE2451B6E4228DC861
      Basic dosing orientation
      The existing GlobalRPh dose and preparation quick reference loads automatically below. Treat it as historical continuity, then confirm the exact current DailyMed label, population, indication, renal function, and institutional policy.
      Source IDH51-58C4434BDB84DC8B949E480B
      Administration orientation
      Route, dilution, concentration, and administration details load automatically from the existing GlobalRPh quick reference below; current exact-product verification remains required.
      Source IDH51-E7EE9B89BD90552B9DCA1478
      Renal and population orientation
      Separate renal reference: Open Renal Dosing Master (opens in a new tab)Renal dosing status has not been locally normalized; use the current package insert before ordering or administration.
      Source IDH51-9222CAF40616A1405BA8FB95
      Key safety orientation
      1. Legacy content must be reconciled against current labeling and institutional policy before clinical use.
        Source IDH51-1E6BB1F1FF0CD015D5F25A6B
      Coverage path
      automatic_legacy_quick_reference
      Source IDH51-176E0CB258F7AFF236347CB7
      Coverage path label
      Automatic legacy GlobalRPh quick reference
      Source IDH51-90CE30C831F10EA9E11F035D
      Legacy title
      Adakveo (crizanlizumab-tmca)
      Source IDH51-79467E417FE07F6DEA62340A
      Review note
      First-look orientation only. Verify indication, patient population, weight basis, organ function, exact IV product, dose, concentration, compatibility, rate, and current labeling before use.
      Source IDH51-FC283276CE35C14EB71BA959
      Search text
      Adakveo (crizanlizumab-tmca) Biologics and immunotherapy Legacy GlobalRPh directory entry The current labeled immune, hematologic, neurologic, metabolic, or inflammatory indication for this targeted biologic. Binds P-selectin and reduces adhesion among activated endothelium, platelets, leukocytes, and sickled erythrocytes. The existing GlobalRPh dose and preparation quick reference loads automatically below. Treat it as historical continuity, then confirm the exact current DailyMed label, population, indication, renal function, and institutional policy. Route, dilution, concentration, and administration details load automatically from the existing GlobalRPh quick reference below; current exact-product verification remains required. Renal dosing status has not been locally normalized; use the current package insert before ordering or administration. Legacy content must be reconciled against current labeling and institutional policy before clinical use. Automatic legacy GlobalRPh quick reference
      Source IDH51-4C9AF26476322679B210E570
      Official access mode
      none
      Source IDH51-7054ABB819C550ABF9B770CE
      Official access reason
      No source-backed DailyMed action has been verified for this umbrella or legacy record; identify the exact product before searching.
      Source IDH51-EFB329E5EF327456B0DA4C5E

      No separate structured rows were bundled for preparation, IV push, continuous infusion, population dosing, dialysis, CRRT. Historical article content and source links may cover these topics.

      Historical renal-function guidance

      Recovered v5.1 source content; historical, awaiting current review.

      Separate renal reference: Open Renal Dosing Master (opens in a new tab)
      Classification
      current_label_review_required
      Source IDH51-F00DC1AC30A316FAA26CB4F8
      Summary
      Renal dosing status has not been locally normalized; use the current package insert before ordering or administration.
      Source IDH51-9147C62D66A52661790E4479
      Method note
      Use the renal function estimate and body-size convention specified by the selected label or institutional protocol. Do not interchange Cockcroft-Gault CrCl, indexed eGFR, and de-indexed eGFR without confirming the dosing source.
      Source IDH51-B9CCBF9DBBF72D1D555D6131

      Historical Warnings and safeguards

      Recovered v5.1 source content; historical, awaiting current review.

      1. Legacy content must be reconciled against current labeling and institutional policy before clinical use.
        Source IDH51-1ACF03BCAFB6022BB99A6121

      Historical Stability notes

      Recovered v5.1 source content; historical, awaiting current review.

      1. Legacy product stability information is not automatically equivalent to a USP <797> BUD.
        Source IDH51-2EC9B840ADF39BAB9963733B
      Other recovered source fields and original editorial metadata

      Original status words such as current, verified, or normalized describe the historical source release. They do not change the clinical review status of this release.

      Catalog source fields

      Id
      adakveo-crizanlizumab-tmca
      Source IDH51-125786DACFE8501CEDA0724D
      Legacy title
      Adakveo (crizanlizumab-tmca)
      Source IDH51-8A3D1177F68698DFA7DDC17D
      Generic name
      Adakveo (crizanlizumab-tmca)
      Source IDH51-F7D82FA03BE989C521947275
      Class
      Biologics and immunotherapy
      Source IDH51-381D1FE7AE5E3E06D2BF9E8C
      Subclass
      Legacy GlobalRPh directory entry
      Source IDH51-67F0BA499039134EE267D599
      Summary
      Existing GlobalRPh IV dilution monograph retained for migration into the unified reference.
      Source IDH51-D12D8894F1F70048578CF900
      Populations
      1. Population not yet normalized
        Source IDH51-FA0253EAAB03F42EFCED2AD0
      Evidence tier
      Legacy catalog - migration review required
      Source IDH51-47849F74D3EAD67FA6E8CE6E
      High alert
      false
      Source IDH51-E394086F2D8A18FFFDF4B543
      Hazardous
      false
      Source IDH51-93ECAEECD503B4A71C03B7DF
      Status
      Legacy migration
      Source IDH51-3E4E967A004EB525AB9E07DE
      Version added
      Legacy
      Source IDH51-7C6FDEF90A383CB76D77B4F6
      Sources
      LabelUrlKind
      Source IDH51-0DC70E4EB6F21F2B777C6E88
      GlobalRPh legacy IV dilution monograph
      Source IDH51-5B6163F443F5EF0B1CAF7CF4
      		legacy:auto
      Source IDH51-C1B80D91B7AB733F5232A9D3
      		Legacy
      Source IDH51-BDC67FB2D444FDD37233C2E7
      Clinical release verification
      Audit version
      3.4
      Source IDH51-C153D177E3FE384A96CA2016
      Audited on
      2026-08-30
      Source IDH51-60F845A8F7A05D96340FC07B
      Level
      red
      Source IDH51-88FA37AE6BD1165564C272F7
      Release gate
      unverified_or_unclassified_sources_do_not_release_as_current
      Source IDH51-0EBC15CC8FF2A8E158458959
      Exact current label candidate
      false
      Source IDH51-7AD0067C27D25236A16239EF
      Reference url count
      0
      Source IDH51-CC915D5C1C2D9EFFD496366F
      Broken reference count
      0
      Source IDH51-744625CF2EBDCB5F9A18B98E
      Point of use confirmation required
      true
      Source IDH51-2C2B6E990A47DC6447284799
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-FAB4693D828295ADFF997F54

      Dosing source fields

      Id
      adakveo-crizanlizumab-tmca
      Source IDH51-38492A05A19075E5490CC555
      Generic name
      Adakveo (crizanlizumab-tmca)
      Source IDH51-056E12640EEA099BBAB741A5
      Coverage status
      direct_official_label_access_plus_legacy_reference
      Source IDH51-1F2013D270265A5CC8697447
      Package insert
      Query name
      Adakveo
      Source IDH51-50B1075FEB812124A33FBEBE
      Product and route must match
      true
      Source IDH51-3C496DB9220038FD55C1481A
      Live current label enabled
      false
      Source IDH51-9EACC65847DCA7AFF1B3183D
      Source priority
      Reviewed local summary when available, then a verified DailyMed label or product search when available, followed by professional references and institutional policy.
      Source IDH51-D1BB09B51E105EABB440D9DF
      Direct official label access enabled
      true
      Source IDH51-47B56E13AAD316249E57D400
      Outbound server request required
      false
      Source IDH51-FEF8595DD79A5EEAC0651C87
      Local summary status
      not_bundled
      Source IDH51-7C875B0DB7CFB482D4FCFCF3
      Clinical review
      Locally normalized
      false
      Source IDH51-BCD3C2AB3AFCC2040C791506
      Reviewed
      2026-08-29
      Source IDH51-A0BE8231F5156CCB0FFFAB82
      Status
      Direct official package-insert access enabled; indication-specific local normalization pending.
      Source IDH51-F700779BFB27EC4A5AF0F1F8
      Clinical release verification
      Audit version
      3.4
      Source IDH51-89BBB6F4F83E75EADE5787FC
      Audited on
      2026-08-30
      Source IDH51-288F93239EE748C493D04E0C
      Level
      red
      Source IDH51-66951155C8A77166B3A37C25
      Release gate
      unverified_or_unclassified_sources_do_not_release_as_current
      Source IDH51-41241E0E34065476D5B2F08B
      Exact current label candidate
      false
      Source IDH51-268DEC632BA09E592063051D
      Reference url count
      0
      Source IDH51-E5C49AB9F3B1362AC0678265
      Broken reference count
      0
      Source IDH51-7ADDD7310C37882EF403ED27
      Point of use confirmation required
      true
      Source IDH51-879FF1EF73A41015F0847873
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-647F2C380967A83DDDDFAE4A
      Historical preparation assessment

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      adakveo-crizanlizumab-tmca
      Source IDH51-F28E24128F7CDAE386C40E98
      Name
      Adakveo (crizanlizumab-tmca)
      Source IDH51-ED3F5A1CEB0F13EACE4AEAD6
      Therapeutic class
      Biologics and immunotherapy
      Source IDH51-1E3FB2BE1231CE304A836626
      Review version
      3.1
      Source IDH51-1FB8480DFD9E3C1F8661C7CE
      Review date
      2026-08-30
      Source IDH51-6F4F5E07CDA8A9B69C8D8AF8
      Release status
      no_released_dilution_current_label_review_required
      Source IDH51-769534071AF123A33B61938D
      Market status
      Status
      no_current_us_iv_spl_confirmed
      Source IDH51-7C4F433CF217DF6128A5A9C9
      Basis
      No high-confidence current IV SPL was automatically selected; legacy information is segregated
      Source IDH51-0A95D441DD89110BE77DDA20
      Ten point assessment
      Exact formulation
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-AD6081D70B17572237B322C0
      Reconstitution concentration
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-6A05B78560DA1481BFF63359
      Maximum or recommended final concentration
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-817D7A81F515B9250C9A37C0
      Appropriate standardized containers
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-A5CF837B9764703A0D0A4E00
      Adult dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-41B0010B07351B63E82A83FD
      Pediatric dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-369A2B3B9B60256BCDB57E99
      Neonatal dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-C5B38A10FD68B45E6E1D519B
      Infusion time
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-896A53FA11986E75363D6300
      Fluid restriction alternatives
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-1B29FC6578001A7A6DBBF016
      Current manufacturer labeling
      Match confidence
      unresolved
      Source IDH51-CC703FF6829B6462D94367DD
      Field provenance
      Exact formulation
      Primary
      not_found
      Source IDH51-77BF3C489C1EDD361890884C
      Reconstitution concentration
      Primary
      not_found
      Source IDH51-C3BB25FD7C2150F92850853A
      Maximum or recommended final concentration
      Primary
      not_found
      Source IDH51-BD7C8E2269A60E416CA5D1C4
      Appropriate standardized containers
      Primary
      not_found
      Source IDH51-4D47E79FBB10C55945933549
      Adult dosing range
      Primary
      not_found
      Source IDH51-ED049F339B9A3545E2043F68
      Pediatric dosing range
      Primary
      not_found
      Source IDH51-AE03779A19C492F48E29E115
      Neonatal dosing range
      Primary
      not_found
      Source IDH51-4BDBA1BD77E755955CD4EAE1
      Infusion time
      Primary
      not_found
      Source IDH51-F24B143D38EE33263A997BA7
      Fluid restriction alternatives
      Primary
      not_found
      Source IDH51-8E8FE2B9B75BE3CC0F768341
      Current manufacturer labeling
      Primary
      DailyMed search gateway
      Source IDH51-8D30104EF2BD7AB3421E5733
      Population applicability
      Adult
      Applicability
      not_established
      Source IDH51-6245CC4303B0081E1532F14D
      Guide generation allowed
      false
      Source IDH51-B864C4FDC69ED6B7821CE3E6
      Pediatric
      Applicability
      not_established
      Source IDH51-B86D8A3804A4D915DCDDC274
      Guide generation allowed
      false
      Source IDH51-612426A565AA21FACB8FC9DF
      Neonatal
      Applicability
      not_established
      Source IDH51-2229E176F4AABF4302A4EB74
      Guide generation allowed
      false
      Source IDH51-CD01974F69140910F2CC4DFA
      Route presence
      Structured dilution
      false
      Source IDH51-7537C152382C1817A6E87743
      Iv push
      false
      Source IDH51-7F4BC8AD75CF352FCB61FB92
      Continuous infusion
      false
      Source IDH51-F3AF6E53C137904EE2C2A6CE
      Pediatric source
      false
      Source IDH51-65891802BAA9AD1EC76ED911
      Neonatal source
      false
      Source IDH51-FB9AEDFB45382F3E09A6A785
      Legacy reference
      Status
      not_available
      Source IDH51-902AA297DA145A59D70ACC31
      Label resolution
      Status
      build_environment_network_unavailable
      Source IDH51-435172664486F833FE5CDF3F
      Source files
      1. catalog.json
        Source IDH51-2254A577245660D88BD9A954
      2. dosing.json
        Source IDH51-B4EB6C908A40721B8B0292E8
      3. legacy-map.json
        Source IDH51-3E5B9CAA5061405879ED97D3
      4. review-queue.json
        Source IDH51-8B848814DD4B920C047E5903
      Clinical release note
      Preparation instructions are released only at the evidence level shown. Legacy content remains visibly separate. Exact product, NDC, route, current labeling, and institutional policy must be confirmed.
      Source IDH51-41BEA9A27879754D21D8FEFA
      Historical statement IDs and source locations

      These IDs identify recovered source units. They are not evidence-qualified clinical claims.

      Historical IDOriginal source locationStatus
      H51-125786DACFE8501CEDA0724Dcatalog.json
      /records/5/id      		Historical; current review incomplete
      H51-8A3D1177F68698DFA7DDC17Dcatalog.json
      /records/5/legacy_title      		Historical; current review incomplete
      H51-F7D82FA03BE989C521947275catalog.json
      /records/5/generic_name      		Historical; current review incomplete
      H51-381D1FE7AE5E3E06D2BF9E8Ccatalog.json
      /records/5/class      		Historical; current review incomplete
      H51-67F0BA499039134EE267D599catalog.json
      /records/5/subclass      		Historical; current review incomplete
      H51-D12D8894F1F70048578CF900catalog.json
      /records/5/summary      		Historical; current review incomplete
      H51-1ACF03BCAFB6022BB99A6121catalog.json
      /records/5/warnings/0      		Historical; current review incomplete
      H51-2EC9B840ADF39BAB9963733Bcatalog.json
      /records/5/stability_notes/0      		Historical; current review incomplete
      H51-FA0253EAAB03F42EFCED2AD0catalog.json
      /records/5/populations/0      		Historical; current review incomplete
      H51-47849F74D3EAD67FA6E8CE6Ecatalog.json
      /records/5/evidence_tier      		Historical; current review incomplete
      H51-E394086F2D8A18FFFDF4B543catalog.json
      /records/5/high_alert      		Historical; current review incomplete
      H51-93ECAEECD503B4A71C03B7DFcatalog.json
      /records/5/hazardous      		Historical; current review incomplete
      H51-3E4E967A004EB525AB9E07DEcatalog.json
      /records/5/status      		Historical; current review incomplete
      H51-472541FD1C1D8CFDA9294BD1catalog.json
      /records/5/reviewed      		Historical; current review incomplete
      H51-7C6FDEF90A383CB76D77B4F6catalog.json
      /records/5/version_added      		Historical; current review incomplete
      H51-0DC70E4EB6F21F2B777C6E88catalog.json
      /records/5/sources/0      		Historical; current review incomplete
      H51-5B6163F443F5EF0B1CAF7CF4catalog.json
      /records/5/sources/0/label      		Historical; current review incomplete
      H51-C1B80D91B7AB733F5232A9D3catalog.json
      /records/5/sources/0/url      		Historical; current review incomplete
      H51-BDC67FB2D444FDD37233C2E7catalog.json
      /records/5/sources/0/kind      		Historical; current review incomplete
      H51-C153D177E3FE384A96CA2016catalog.json
      /records/5/clinical_release_verification/audit_version      		Historical; current review incomplete
      H51-60F845A8F7A05D96340FC07Bcatalog.json
      /records/5/clinical_release_verification/audited_on      		Historical; current review incomplete
      H51-88FA37AE6BD1165564C272F7catalog.json
      /records/5/clinical_release_verification/level      		Historical; current review incomplete
      H51-0EBC15CC8FF2A8E158458959catalog.json
      /records/5/clinical_release_verification/release_gate      		Historical; current review incomplete
      H51-7AD0067C27D25236A16239EFcatalog.json
      /records/5/clinical_release_verification/exact_current_label_candidate      		Historical; current review incomplete
      H51-17A32D3AF7633D0A4432D061catalog.json
      /records/5/clinical_release_verification/selected_setid      		Historical; current review incomplete
      H51-F53F51D6B882ED8F32053DFDcatalog.json
      /records/5/clinical_release_verification/selected_label_title      		Historical; current review incomplete
      H51-DE7912432D6578CE65129CAEcatalog.json
      /records/5/clinical_release_verification/numeric_support_ratio      		Historical; current review incomplete
      H51-CC915D5C1C2D9EFFD496366Fcatalog.json
      /records/5/clinical_release_verification/reference_url_count      		Historical; current review incomplete
      H51-744625CF2EBDCB5F9A18B98Ecatalog.json
      /records/5/clinical_release_verification/broken_reference_count      		Historical; current review incomplete
      H51-2C2B6E990A47DC6447284799catalog.json
      /records/5/clinical_release_verification/point_of_use_confirmation_required      		Historical; current review incomplete
      H51-FAB4693D828295ADFF997F54catalog.json
      /records/5/clinical_release_verification/note      		Historical; current review incomplete
      H51-89EA34501EE47BC59501A74Ecatalog.json
      /records/5/clinical_release_verification/dailymed_search_url      		Historical; current review incomplete
      H51-38492A05A19075E5490CC555dosing.json
      /records/5/id      		Historical; current review incomplete
      H51-056E12640EEA099BBAB741A5dosing.json
      /records/5/generic_name      		Historical; current review incomplete
      H51-1F2013D270265A5CC8697447dosing.json
      /records/5/coverage_status      		Historical; current review incomplete
      H51-50B1075FEB812124A33FBEBEdosing.json
      /records/5/package_insert/query_name      		Historical; current review incomplete
      H51-91448F2CE3B2D08E1FDDE631dosing.json
      /records/5/package_insert/preferred_setid      		Historical; current review incomplete
      H51-3C496DB9220038FD55C1481Adosing.json
      /records/5/package_insert/product_and_route_must_match      		Historical; current review incomplete
      H51-9EACC65847DCA7AFF1B3183Ddosing.json
      /records/5/package_insert/live_current_label_enabled      		Historical; current review incomplete
      H51-D1BB09B51E105EABB440D9DFdosing.json
      /records/5/package_insert/source_priority      		Historical; current review incomplete
      H51-47B56E13AAD316249E57D400dosing.json
      /records/5/package_insert/direct_official_label_access_enabled      		Historical; current review incomplete
      H51-FEF8595DD79A5EEAC0651C87dosing.json
      /records/5/package_insert/outbound_server_request_required      		Historical; current review incomplete
      H51-7C875B0DB7CFB482D4FCFCF3dosing.json
      /records/5/package_insert/local_summary_status      		Historical; current review incomplete
      H51-F00DC1AC30A316FAA26CB4F8dosing.json
      /records/5/renal/classification      		Historical; current review incomplete
      H51-9147C62D66A52661790E4479dosing.json
      /records/5/renal/summary      		Historical; current review incomplete
      H51-B9CCBF9DBBF72D1D555D6131dosing.json
      /records/5/renal/method_note      		Historical; current review incomplete
      H51-BCD3C2AB3AFCC2040C791506dosing.json
      /records/5/clinical_review/locally_normalized      		Historical; current review incomplete
      H51-A0BE8231F5156CCB0FFFAB82dosing.json
      /records/5/clinical_review/reviewed      		Historical; current review incomplete
      H51-F700779BFB27EC4A5AF0F1F8dosing.json
      /records/5/clinical_review/status      		Historical; current review incomplete
      H51-89BBB6F4F83E75EADE5787FCdosing.json
      /records/5/clinical_release_verification/audit_version      		Historical; current review incomplete
      H51-288F93239EE748C493D04E0Cdosing.json
      /records/5/clinical_release_verification/audited_on      		Historical; current review incomplete
      H51-66951155C8A77166B3A37C25dosing.json
      /records/5/clinical_release_verification/level      		Historical; current review incomplete
      H51-41241E0E34065476D5B2F08Bdosing.json
      /records/5/clinical_release_verification/release_gate      		Historical; current review incomplete
      H51-268DEC632BA09E592063051Ddosing.json
      /records/5/clinical_release_verification/exact_current_label_candidate      		Historical; current review incomplete
      H51-055DE92EB732BD8E886AF82Fdosing.json
      /records/5/clinical_release_verification/selected_setid      		Historical; current review incomplete
      H51-1687C0E0A3164458A309971Fdosing.json
      /records/5/clinical_release_verification/selected_label_title      		Historical; current review incomplete
      H51-84FAEF63049E0923BB8DA055dosing.json
      /records/5/clinical_release_verification/numeric_support_ratio      		Historical; current review incomplete
      H51-E5C49AB9F3B1362AC0678265dosing.json
      /records/5/clinical_release_verification/reference_url_count      		Historical; current review incomplete
      H51-7ADDD7310C37882EF403ED27dosing.json
      /records/5/clinical_release_verification/broken_reference_count      		Historical; current review incomplete
      H51-879FF1EF73A41015F0847873dosing.json
      /records/5/clinical_release_verification/point_of_use_confirmation_required      		Historical; current review incomplete
      H51-647F2C380967A83DDDDFAE4Adosing.json
      /records/5/clinical_release_verification/note      		Historical; current review incomplete
      H51-B0F3449B7CF57FD0BBA4BED5dosing.json
      /records/5/clinical_release_verification/dailymed_search_url      		Historical; current review incomplete
      H51-C846A25DE9F6BD4874808DBAfirst-look-v5.1.json
      /records/5/id      		Historical; current review incomplete
      H51-FFF10DCFD5F0DC588EF00371first-look-v5.1.json
      /records/5/generic_name      		Historical; current review incomplete
      H51-EB39EAD7C3C90D8C06E513C7first-look-v5.1.json
      /records/5/class      		Historical; current review incomplete
      H51-93015B6517D78CD3D4807F79first-look-v5.1.json
      /records/5/subclass      		Historical; current review incomplete
      H51-E1CD5393E5BD7299C9D9CC17first-look-v5.1.json
      /records/5/primary_uses/0      		Historical; current review incomplete
      H51-9A810FCE155B8E94855B7F1Ffirst-look-v5.1.json
      /records/5/mechanism      		Historical; current review incomplete
      H51-C15D95DE2451B6E4228DC861first-look-v5.1.json
      /records/5/mechanism_level      		Historical; current review incomplete
      H51-58C4434BDB84DC8B949E480Bfirst-look-v5.1.json
      /records/5/basic_dosing_orientation      		Historical; current review incomplete
      H51-E7EE9B89BD90552B9DCA1478first-look-v5.1.json
      /records/5/administration_orientation      		Historical; current review incomplete
      H51-9222CAF40616A1405BA8FB95first-look-v5.1.json
      /records/5/renal_and_population_orientation      		Historical; current review incomplete
      H51-1E6BB1F1FF0CD015D5F25A6Bfirst-look-v5.1.json
      /records/5/key_safety_orientation/0      		Historical; current review incomplete
      H51-176E0CB258F7AFF236347CB7first-look-v5.1.json
      /records/5/coverage_path      		Historical; current review incomplete
      H51-90CE30C831F10EA9E11F035Dfirst-look-v5.1.json
      /records/5/coverage_path_label      		Historical; current review incomplete
      H51-DDEDAEB72381C6A912EA9266first-look-v5.1.json
      /records/5/official_label_url      		Historical; current review incomplete
      H51-79467E417FE07F6DEA62340Afirst-look-v5.1.json
      /records/5/legacy_title      		Historical; current review incomplete
      H51-FC283276CE35C14EB71BA959first-look-v5.1.json
      /records/5/review_note      		Historical; current review incomplete
      H51-4C9AF26476322679B210E570first-look-v5.1.json
      /records/5/search_text      		Historical; current review incomplete
      H51-83A3EEC9FD4ADB093D150F3Ffirst-look-v5.1.json
      /records/5/official_search_url      		Historical; current review incomplete
      H51-7054ABB819C550ABF9B770CEfirst-look-v5.1.json
      /records/5/official_access_mode      		Historical; current review incomplete
      H51-E5537675CD3556E586A477A7first-look-v5.1.json
      /records/5/official_access_url      		Historical; current review incomplete
      H51-48DE8F74B21C758436815D2Cfirst-look-v5.1.json
      /records/5/official_search_query      		Historical; current review incomplete
      H51-EFB329E5EF327456B0DA4C5Efirst-look-v5.1.json
      /records/5/official_access_reason      		Historical; current review incomplete
      H51-F28E24128F7CDAE386C40E98preparation-assessments-v3.8.json
      /5/id      		Historical; current review incomplete
      H51-ED3F5A1CEB0F13EACE4AEAD6preparation-assessments-v3.8.json
      /5/name      		Historical; current review incomplete
      H51-9646B4745D82B1482E311FC9preparation-assessments-v3.8.json
      /5/brands      		Historical; current review incomplete
      H51-1E3FB2BE1231CE304A836626preparation-assessments-v3.8.json
      /5/therapeutic_class      		Historical; current review incomplete
      H51-1FB8480DFD9E3C1F8661C7CEpreparation-assessments-v3.8.json
      /5/review_version      		Historical; current review incomplete
      H51-6F4F5E07CDA8A9B69C8D8AF8preparation-assessments-v3.8.json
      /5/review_date      		Historical; current review incomplete
      H51-769534071AF123A33B61938Dpreparation-assessments-v3.8.json
      /5/release_status      		Historical; current review incomplete
      H51-7C4F433CF217DF6128A5A9C9preparation-assessments-v3.8.json
      /5/market_status/status      		Historical; current review incomplete
      H51-0A95D441DD89110BE77DDA20preparation-assessments-v3.8.json
      /5/market_status/basis      		Historical; current review incomplete
      H51-AD6081D70B17572237B322C0preparation-assessments-v3.8.json
      /5/ten_point_assessment/exact_formulation      		Historical; current review incomplete
      H51-6A05B78560DA1481BFF63359preparation-assessments-v3.8.json
      /5/ten_point_assessment/reconstitution_concentration      		Historical; current review incomplete
      H51-817D7A81F515B9250C9A37C0preparation-assessments-v3.8.json
      /5/ten_point_assessment/maximum_or_recommended_final_concentration      		Historical; current review incomplete
      H51-A5CF837B9764703A0D0A4E00preparation-assessments-v3.8.json
      /5/ten_point_assessment/appropriate_standardized_containers      		Historical; current review incomplete
      H51-41B0010B07351B63E82A83FDpreparation-assessments-v3.8.json
      /5/ten_point_assessment/adult_dosing_range      		Historical; current review incomplete
      H51-369A2B3B9B60256BCDB57E99preparation-assessments-v3.8.json
      /5/ten_point_assessment/pediatric_dosing_range      		Historical; current review incomplete
      H51-C5B38A10FD68B45E6E1D519Bpreparation-assessments-v3.8.json
      /5/ten_point_assessment/neonatal_dosing_range      		Historical; current review incomplete
      H51-896A53FA11986E75363D6300preparation-assessments-v3.8.json
      /5/ten_point_assessment/infusion_time      		Historical; current review incomplete
      H51-1B29FC6578001A7A6DBBF016preparation-assessments-v3.8.json
      /5/ten_point_assessment/fluid_restriction_alternatives      		Historical; current review incomplete
      H51-4614FB6F440A5B2763CB2D42preparation-assessments-v3.8.json
      /5/ten_point_assessment/current_manufacturer_labeling/setid      		Historical; current review incomplete
      H51-3F45013C60F3B40252C5CA00preparation-assessments-v3.8.json
      /5/ten_point_assessment/current_manufacturer_labeling/title      		Historical; current review incomplete
      H51-D0319D5681A133AB239A6CDEpreparation-assessments-v3.8.json
      /5/ten_point_assessment/current_manufacturer_labeling/published_date      		Historical; current review incomplete
      H51-A7FE0973B74194C7A41781E8preparation-assessments-v3.8.json
      /5/ten_point_assessment/current_manufacturer_labeling/manufacturer      		Historical; current review incomplete
      H51-CC703FF6829B6462D94367DDpreparation-assessments-v3.8.json
      /5/ten_point_assessment/current_manufacturer_labeling/match_confidence      		Historical; current review incomplete
      H51-68FA2420BADD7E4EE77FEB8Apreparation-assessments-v3.8.json
      /5/ten_point_assessment/current_manufacturer_labeling/url      		Historical; current review incomplete
      H51-77BF3C489C1EDD361890884Cpreparation-assessments-v3.8.json
      /5/field_provenance/exact_formulation/primary      		Historical; current review incomplete
      H51-C3BB25FD7C2150F92850853Apreparation-assessments-v3.8.json
      /5/field_provenance/reconstitution_concentration/primary      		Historical; current review incomplete
      H51-BD7C8E2269A60E416CA5D1C4preparation-assessments-v3.8.json
      /5/field_provenance/maximum_or_recommended_final_concentration/primary      		Historical; current review incomplete
      H51-4D47E79FBB10C55945933549preparation-assessments-v3.8.json
      /5/field_provenance/appropriate_standardized_containers/primary      		Historical; current review incomplete
      H51-ED049F339B9A3545E2043F68preparation-assessments-v3.8.json
      /5/field_provenance/adult_dosing_range/primary      		Historical; current review incomplete
      H51-AE03779A19C492F48E29E115preparation-assessments-v3.8.json
      /5/field_provenance/pediatric_dosing_range/primary      		Historical; current review incomplete
      H51-4BDBA1BD77E755955CD4EAE1preparation-assessments-v3.8.json
      /5/field_provenance/neonatal_dosing_range/primary      		Historical; current review incomplete
      H51-F24B143D38EE33263A997BA7preparation-assessments-v3.8.json
      /5/field_provenance/infusion_time/primary      		Historical; current review incomplete
      H51-8E8FE2B9B75BE3CC0F768341preparation-assessments-v3.8.json
      /5/field_provenance/fluid_restriction_alternatives/primary      		Historical; current review incomplete
      H51-8D30104EF2BD7AB3421E5733preparation-assessments-v3.8.json
      /5/field_provenance/current_manufacturer_labeling/primary      		Historical; current review incomplete
      H51-6245CC4303B0081E1532F14Dpreparation-assessments-v3.8.json
      /5/population_applicability/adult/applicability      		Historical; current review incomplete
      H51-B864C4FDC69ED6B7821CE3E6preparation-assessments-v3.8.json
      /5/population_applicability/adult/guide_generation_allowed      		Historical; current review incomplete
      H51-B86D8A3804A4D915DCDDC274preparation-assessments-v3.8.json
      /5/population_applicability/pediatric/applicability      		Historical; current review incomplete
      H51-612426A565AA21FACB8FC9DFpreparation-assessments-v3.8.json
      /5/population_applicability/pediatric/guide_generation_allowed      		Historical; current review incomplete
      H51-2229E176F4AABF4302A4EB74preparation-assessments-v3.8.json
      /5/population_applicability/neonatal/applicability      		Historical; current review incomplete
      H51-CD01974F69140910F2CC4DFApreparation-assessments-v3.8.json
      /5/population_applicability/neonatal/guide_generation_allowed      		Historical; current review incomplete
      H51-7537C152382C1817A6E87743preparation-assessments-v3.8.json
      /5/route_presence/structured_dilution      		Historical; current review incomplete
      H51-7F4BC8AD75CF352FCB61FB92preparation-assessments-v3.8.json
      /5/route_presence/iv_push      		Historical; current review incomplete
      H51-F3AF6E53C137904EE2C2A6CEpreparation-assessments-v3.8.json
      /5/route_presence/continuous_infusion      		Historical; current review incomplete
      H51-65891802BAA9AD1EC76ED911preparation-assessments-v3.8.json
      /5/route_presence/pediatric_source      		Historical; current review incomplete
      H51-FB9AEDFB45382F3E09A6A785preparation-assessments-v3.8.json
      /5/route_presence/neonatal_source      		Historical; current review incomplete
      H51-902AA297DA145A59D70ACC31preparation-assessments-v3.8.json
      /5/legacy_reference/status      		Historical; current review incomplete
      H51-435172664486F833FE5CDF3Fpreparation-assessments-v3.8.json
      /5/label_resolution/status      		Historical; current review incomplete
      H51-2254A577245660D88BD9A954preparation-assessments-v3.8.json
      /5/source_files/0      		Historical; current review incomplete
      H51-B4EB6C908A40721B8B0292E8preparation-assessments-v3.8.json
      /5/source_files/1      		Historical; current review incomplete
      H51-3E5B9CAA5061405879ED97D3preparation-assessments-v3.8.json
      /5/source_files/2      		Historical; current review incomplete
      H51-8B848814DD4B920C047E5903preparation-assessments-v3.8.json
      /5/source_files/3      		Historical; current review incomplete
      H51-41BEA9A27879754D21D8FEFApreparation-assessments-v3.8.json
      /5/clinical_release_note      		Historical; current review incomplete

      Open the original GlobalRPh site monograph (historical; not revalidated) (opens in a new tab)

      All medicationsReturn to medication headingApplication top